Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma-Experience from Asian Countries.
Journal
Clinical lymphoma, myeloma & leukemia
Journal Volume
26
Journal Issue
2
Start Page
e241
End Page
e247
ISSN
2152-2669
Date Issued
2026-02
Author(s)
Soekojo, Cinnie
Chung, Shimin Jasmine
Tsai, Ming-Tao
Chen, Wenming
Kim, Jin Seok
Lee, Dong-Gun
Min, Chang Ki
Suzuki, Kazuhito
Swaminathan, Subramanian
Takamatsu, Hiroyuki
Tan, Daryl
Yanamandra, Uday
Nagarajan, Chandramouli
Chng, Wee Joo
Abstract
Background: The management of relapsed / refractory myeloma particularly those who are heavily pretreated and penta-refractory has experienced a paradigm change with the advent of bispecific antibodies targeting B-cell maturation antigen (BCMA), offering new hope for these patients. The diverse experiences in the use of bispecific antibodies across Asian countries/regions underscore the complexities of integrating these therapies into clinical practice. With limited availability and varying access through clinical trials, compassionate access programmes and early commercial use, these agents are demonstrating impressive efficacy, yet present unique challenges in widespread adoption of these agents. Methods: A roundtable discussion among myeloma experts from Asia has highlighted consistent efficacy but also raised concerns about the durability of response and the management of associated toxicities and infections. Results: These discussions emphasize the need for ongoing research to better understand the nuances of treatment sequencing and patient selection. Conclusions: The insights gained will contribute to developing strategic frameworks and consensus guidelines that can effectively guide clinicians in optimizing outcomes for myeloma patients in diverse healthcare settings.
Subjects
Bispecifics
Elranatamab
Linvoseltamab
Teclistamab
Type
journal article